



APR 0 7 2004 B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

olicant: Kazuma TOMIZUKA et al.

Title:

METHOD FOR MODIFYING CHROMOSOMES

Appl. No.:

09/763,362

Filing Date:

04/23/2001

Examiner:

Thaian N. Ton

Art Unit:

1632

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.



RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(2) that no item of information contained in this supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the supplemental information disclosure statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, postdated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER LLP

Washington Harbour

3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5143

Telephone:

(202) 672-5404

(202) 672-5399 Facsimile:

Stephen A. Bent Attorney for Applicant Registration No. 29,768

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

					ALP &	
Substitute for	r form 1449B/	PTO		Complete if Known	101,67	
INFORMATIO	אי טופכו סי	SURF	Application Number	09/763,362	/ "	₹
				04/23/2001	100-0-7	<u>•</u>
				Kazuma TOMIZUKA	APR U / 2004	ابير
Date Submit	ted: April 7,	2004		1632	P	<u>z/</u>
(vec on many s	hoote as no	cessan/)		Thaian N. Ton	The state of the s	<u> </u>
1		1		081356-0158	PRADEMAN	
	Substitute for INFORMATION STATEMENT Date Submit	Substitute for form 1449B/ INFORMATION DISCLOS STATEMENT BY APPLIC Date Submitted: April 7,	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 7, 2004 (use as many sheets as necessary)	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 7, 2004 (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 7, 2004 (use as many sheets as necessary) Complete if Known Application Number Filing Date Filing Date First Named Inventor Group Art Unit Examiner Name Thaian N. Ton Attacks Positet Number O81356-0158	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 7, 2004 (use as many sheets as necessary) Complete if Known 09/763,362 Filing Date Filing Date First Named Inventor Group Art Unit Examiner Name Thaian N. Ton OR1356-0158

				U.S. PATENT DOCUMENTS		
Eveminer	Cite	U.S. Patent (Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
Examiner Initials*	No. ¹	Number	Kind Code ² (if known)	Cited Document	MM-DD-YYYY	Figures Appear

			-	FC	REIGN PATENT DOCUMEN	TS	Danie Calumna Linea	т
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent D	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т ⁶
-		1-						

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Supplementary European Search Report	
		Masahiko TANIGUCHI et al., "Efficient production of Cre-mediated site-directed recombinants through the utilization of the puromycin resistance gene, pac: a transient gene-integration marker for ES cells", Nucleic	
		J.C. VAZQUEZ et al., "Factors affecting the efficiency of introducing precise genetic changes in ES cells by homologous recombination: tag-and-exchange versus the Cre-loxp system", Transgenic Research 7, pp.	
		Sara GAGNETEN et al., "Brief expression of a GFP cre fusion gene in embryonic stem cells allows rapid retrieval of site-specific genomic deletions", Nucleic Acids Research, 1997, Vol. 25, No. 16, pp. 3326-3331.	
		Nicholas P. DAVIES et al., "Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin κ Locus", Biotechnology, vol. 11, August 1993, pp. 911-914.	
		Michael J. MENDEZ et al., "Analysis of the Structural Integrity of YACs Comprising Human Immunoglobulin Genes in Yeast and in Embryonic Stem Cells", Genomics 26, pp. 294-307, (1995).	
		Howard COOKE, "Non-programmed and Engineered Chromosome Breakage", COLD SPRING HARBOR MONOGRAPH SERIES; TELOMERES, 1995, pp. 219-245, Cold Spring Harbor Laboratory Press {a}, 10 Skyline Drive, Plainview, New York 11803, USA Series: Cold Spring Harbor Monograph Series (ISSN 0270-1847) ISBN: 0-87969-457-2.	
		R. HELLER et al., "Mini-chromosomes derived from the human Y chromosome by telomere directed chromosome breakage", Genetics, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 7125-7130, 7/1996.	
		K.A. HENNING et al., "Methods in Molecular Genetics, Vol. Techniques and Applications of Microcell-Mediated Chromosome Transfer to Mammalian Cells" METHODS IN MOLECULAR GENETICS, VOL. 1, GENE AND CHROMOSOME ANALYSIS, part A, 1993, pp. 134-150.	

Examiner Signature Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.